COMP <GO>
NATR vs AKBA // EV/EBITDA & P/E VALUATION
Nature's Sunshine Products Inc. (NASDAQ) VS. Akebia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NATR 5
— AKBA 5
▲ EV/EBITDA & P/E VALUATION LEADER: NATR
LAST: $12.25 (-0.24%) • MKT CAP: $216.1M
valuation
4.0x
LAST: $0.71 (-4.81%) • MKT CAP: $205.7M
valuation
4.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATR VS. AKBA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NATR | AKBA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 72.40% | 83.30% | -10.90 | AKBA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.90% | 85.00% | -56.10 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 4.0x | 4.3x | -0.30 | NATR | /valuation <GO> |
| Free Cash Flow Yield | 13.35% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 5.20% | 9.90% | -4.70 | AKBA | /operating-margins <GO> |
| Net Profit Margin | 4.10% | -2.20% | +6.30 | NATR | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 47.50% | -41.80 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.33 | 0.20 | +4.13 | NATR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | NATR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 45.2 | -3.45 | AKBA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $216.1M | $205.7M | $10.4M | NATR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NATR REV | AKBA REV | NATR GROSS % | AKBA GROSS % | NATR FCF | AKBA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $480.1M | $236.2M | 72.4% | 83.3% | $28.8M | $67.7M |
| FY 2024 | $454.4M | $160.2M | 71.5% | 60.6% | $14.3M | -$40.7M |
| FY 2023 | $445.3M | $194.6M | — | — | $41.2M | -$23.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATR // BETA —
AKBA // BETA —